Latest from Bristows - Page 6
Naked and Afraid: Intel re-fined €376.3m for naked restrictions
29.09.2023
On 22 September 2023, the European Commission (“EC”) re-imposed a €376.3 million fine on Intel for ‘naked restrictions’ in the computer chips market between 2002 and 2006, continuing a saga that has been running since at least 2007.
Background
In 2009, the EC fined Intel €1.06 billion for abusing its dominant position in the
Victoria Yuan quoted in Equity Report on Optum/EMIS
29.09.2023
EU and UK competition law expert, Victoria Yuan, has been quoted in Equity Report article dated 26 September, ‘CMA appears unlikely to reverse provisional decision on UnitedHealth Group/EMIS merger’.
Equity Report is a UK-based specialist news service covering M&A, antitrust, and ESG issues from a global perspective. The piece summarises the CMA’s Phase
Podcast: Managing employee DSARs
26.09.2023
15 minutes
In this episode of Legitimately Interesting, data protection experts Hannah Crowther and Jamie Drucker identify six tips for managing employee DSARs. We recommend a pragmatic, risk-based approach – and don’t let perfect be the enemy of the good.
Find all the episodes as we release them here, and don’t forget to
Every Lidl helps: competition in the groceries sector
21.09.2023
The cost of living crisis remains topical as we move to O3 2023. In response to pervasive high food price inflation, the CMA announced in May 2023 that it would be stepping up its work on the grocery sector. The CMA published a 90-page update in July on its work to date, focussing on
‘Tuna bonds’ in Mozambique – Important arbitration decision from the Supreme Court on the proper approach to s.9 of the Arbitration Act 1996
21.09.2023
Yesterday (20 September 2023), the Supreme Court handed down a key decision for all arbitration practitioners on the proper approach to applications under s.9 Arbitration Act 1996. Section 9 allows defendants to legal proceedings brought in breach of an arbitration agreement to apply to the court to stay those proceedings. Section 9 is therefore
Will Microsoft’s call of duty to restructure Activision deal pay off?
Microsoft’s proposed USD 68.7bn acquisition of video games developer Activision Blizzard potentially enters the final level.
21.09.2023
The CMA started its Phase 1 review of the restructured deal[1] on 22 August and the ‘state of play’ stage of the investigation is expected to take place at some point in the week beginning 18 September.[2] In this
The Innovative Devices Access Pathway – expediting access to MedTech
20.09.2023
The UK government has launched the pilot phase of the long-awaited Innovative Devices Access Pathway (IDAP). Applications for participation in the pilot phase opened on 19 September 2023 and the application deadline is 29 October 2023, so would-be participants need to get a move on!
A successful IDAP applicant will receive various non-financial support
DHSC consults on statutory disclosure of industry payments to the healthcare sector
18.09.2023
The Department of Health & Social Care (DHSC) has commenced a public consultation on mandatory disclosure of payments by life sciences companies to the healthcare sector. The UK government intends to introduce an ambitiously broad statutory regime for the public disclosure of each transfer of value (TOV) by a company in the life sciences
First CRISPR therapy seeks regulatory approval, but will it be able to avoid the pitfalls of other cell and gene therapies?
18.09.2023
In a first for CRISPR-based therapies, the FDA, EMA and MHRA have all received regulatory filings for the product exagamglogene autotemcel (“exa-cel”), a treatment for sickle cell disease and transfusion dependent beta-thalassemia. The FDA has since confirmed that it has accepted the regulatory filing for review and has granted priority status to the sickle